Microvascular Complications and Diabetic Retinopathy: Recent Advances and Future Implications

10.1038/eye.2009.108

10.1016/S0039-6257(02)00387-9

10.1167/iovs.05-0096

10.1007/s11892-011-0204-0

10.1001/jama.287.19.2528

10.2337/diabetes.47.6.859

10.2353/ajpath.2010.090398

10.1161/01.RES.0000260182.36481.c9

10.1242/dev.125.9.1591

10.1083/jcb.105.3.1455

10.1038/nm.2052

10.1096/fj.03-1476fje

10.1016/S0002-9440(10)64869-9

10.1111/j.1440-1681.1997.tb02133.x

Roy S , CaglieroE, LorenziM. Fibronectin overexpression in retinal microvessels of patients with diabetes.Invest. Ophthalmol. Vis. Sci.37(2), 258–266 (1996).

10.1016/0014-4835(90)90211-C

10.3109/02713683.2011.607536

10.4103/0301-4738.36480

10.1056/NEJMe058142

10.1056/NEJMoa041773

10.1016/j.ajo.2004.10.004

10.1056/NEJM199412013312203

10.4103/0301-4738.83629

10.2174/157339909787314202

10.1097/ICU.0b013e3282f0ca54

10.1159/000337154

10.1007/s10792-008-9282-7

10.1097/ICU.0b013e3283548459

10.5301/ejo.5000072

10.1016/j.ophtha.2006.05.064

10.1016/j.ophtha.2007.05.062

10.1016/j.ophtha.2005.06.007

10.1196/annals.1348.062

10.2174/157339909787314158

10.1097/IAE.0b013e318206d18c

10.1001/archophthalmol.2010.21

10.2337/db07-0982

10.1016/j.ophtha.2003.05.037

10.1001/archophthalmol.2008.610

10.1016/j.ophtha.2008.06.015

10.2337/diacare.26.9.2653

10.1126/science.272.5262.728

10.1167/iovs.05-0757

10.1097/01.icu.0000143685.60479.3b

10.1097/IAE.0b013e3181fe545f

10.1097/IAE.0b013e3182111669

10.1167/iovs.03-0955

10.1038/sj.eye.6701969

10.1016/j.biocel.2003.08.007

10.1111/j.1464-5491.1985.tb00635.x

10.1155/2007/43603

10.1016/S0899-9007(01)00658-X

10.1089/ars.2005.7.1581

10.1007/s00125-006-0174-y

10.2337/diabetes.53.12.3233

10.1016/S0891-5849(02)01195-4

10.1111/j.1742-1241.1999.tb11820.x

10.1016/S0306-3623(98)00040-8

10.1007/s00417-006-0318-2

10.1167/iovs.02-0985

Galbraith SM , ChaplinDJ, LeeFet al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21(1A), 93–102 (2001).

Dark GG , HillSA, PriseVE, TozerGM, PettitGR, ChaplinDJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.Cancer Res.57(10), 1829–1834 (1997).

10.1111/j.1476-5381.2009.00112.x

10.1167/iovs.10-6351

10.1016/j.mvr.2008.12.003

10.1016/j.drup.2006.04.003

10.1634/theoncologist.2010-0432

10.1001/archopht.1985.01050040118034

10.1016/S0002-9440(10)64612-3

10.1007/s10456-007-9069-x

10.2353/ajpath.2006.050588

10.1016/S0002-9440(10)64773-6

Kwak N , OkamotoN, WoodJM, CampochiaroPA. VEGF is major stimulator in model of choroidal neovascularization.Invest. Ophthalmol. Vis. Sci.41(10), 3158–3164 (2000).

10.1016/S0002-9440(10)65430-2

10.2460/javma.239.4.486

Boyer DS . The ophthotech anti-PDGF in AMD study group. Combined inhibition of platelet derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD) – results of a Phase I study. Invest. Ophthalmol. Vis. Sci.50, e-Abstract 1260 (2009).

10.1038/70963

10.1126/science.276.5319.1706

10.1172/JCI19478

10.1002/jcp.10442

10.1016/j.bbadis.2011.04.007

10.1002/jcb.240290402

10.1126/science.6199844

10.1083/jcb.107.3.1199

10.1073/pnas.83.19.7297

10.1073/pnas.83.7.2091

10.1016/S0002-9440(10)61787-7

10.1016/S0002-9440(10)65619-2

10.1002/1097-4652(200010)185:1<135::AID-JCP13>3.0.CO;2-Y

10.1242/jcs.109.12.2855

10.1124/mol.105.020941

10.1242/jcs.00673

Luna J , TobeT, MousaSA, ReillyTM, CampochiaroPA. Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model.Lab. Invest.75(4), 563–573 (1996).

10.1001/archophthalmol.2009.265

10.1158/1078-0432.CCR-11-0642

10.1091/mbc.4.12.1317

10.1007/BF00046361

10.1073/pnas.84.8.2292

10.1006/bbrc.1999.0248

10.1016/S0092-8674(00)81848-6

10.1074/jbc.275.2.1209

Colorado PC , TorreA, KamphausGet al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 60(9), 2520–2526 (2000).

10.1006/mthe.2002.0702

Mori K , GehlbachP, AndoA, McveyD, WeiL, CampochiaroPA. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor.Invest. Ophthalmol. Vis. Sci.43(7), 2428–2434 (2002).

Mori K , GehlbachP, YamamotoSet al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 43(6), 1994–2000 (2002).

10.1002/jcp.1114

Lai CC , WuWC, ChenSLet al. Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest. Ophthalmol. Vis. Sci. 42(10), 2401–2407 (2001).

10.1172/JCI200421152

10.1096/fj.11-184127

10.1136/bjo.2005.074005

10.1089/hum.2006.17.167

10.1096/fj.05-5046fje

10.2353/ajpath.2009.080788

10.1182/blood-2008-07-170316

10.1016/j.bbrc.2006.04.176

10.1089/104303403321070829

10.1089/104303401750270959

10.1038/sj.gt.3301203

10.1089/104303401750270968

10.1016/S0002-9394(00)00772-8

10.1096/fj.02-0824fje

10.1016/S0002-9440(10)61697-5

10.1167/iovs.06-1280

10.1167/iovs.03-0353

10.3109/10715760903494168

10.1038/labinvest.2010.89

10.1016/S0014-2999(01)01566-7

10.1038/sj.bjp.0704216

10.1167/iovs.10-6768

10.1080/02713680490513146

10.2337/diabetes.50.8.1938

10.2337/diabetes.53.11.2960

10.1167/iovs.04-1210

10.1016/j.exer.2006.07.003

Diabetic retinopathy: future demand to be driven by agents that improve visual acuity. http://decisionresources.com/Products-and-Services/Report.Aspx?R=Dbaspd1408

Hoffmann-La Roche Ltd. www.roche.com/Investors/Ir_Update/Inv-Update-2011–2006–29.Htm

Study evaluating the safety and response of fosbretabulin in asian patients with polypoidal choroidal vasculopathy (PCV). http://clinicaltrials.gov/ct2/show/NCT01023295

Safety and efficacy study of combretastatin A4 phosphate to treat patients with choroidal neovascularization secondary to pathologic myopia. http://clinicaltrials.gov/ct2/show/NCT01423149

A safety and efficacy study of E10030 (anti-PDGF pegylated aptamer) plus lucentis for neovascular age-related macular degeneration. http://clinicaltrials.gov/ct2/show/NCT01089517

A Phase 1 safety study of single and repeated doses of JSM6427 (intravitreal injection) to treat AMD. http://clinicaltrials.gov/ct2/show/NCT00536016

A Phase 1 ascending and parallel group trial to establish the safety tolerability and pharmacokinetics profile of volociximab (alpha 5 beta 1 integrin antagonist) in subjects with neovascular age- related macular degeneration. http://clinicaltrials.gov/show/NCT00782093